Your browser doesn't support javascript.
loading
Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma.
Garcia-Marquez, Maria A; Thelen, Martin; Reinke, Sarah; Keller, Diandra; Wennhold, Kerstin; Lehmann, Jonas; Veldman, Johanna; Borchmann, Sven; Rosenwald, Andreas; Sasse, Stephanie; Diepstra, Arjan; Borchmann, Peter; Engert, Andreas; Klapper, Wolfram; von Bergwelt-Baildon, Michael; Bröckelmann, Paul J; Schlößer, Hans A.
Afiliação
  • Garcia-Marquez MA; Faculty of Medicine and University Hospital of Cologne, Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany. maria.garcia-marquez@uk-koeln.de.
  • Thelen M; Faculty of Medicine and University Hospital of Cologne, Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.
  • Reinke S; Institute of Pathology, University of Kiel, Kiel, Germany.
  • Keller D; Faculty of Medicine and University Hospital of Cologne, Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.
  • Wennhold K; Faculty of Medicine and University Hospital of Cologne, Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.
  • Lehmann J; Faculty of Medicine and University Hospital of Cologne, Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.
  • Veldman J; Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Borchmann S; Faculty of Medicine and University Hospital of Cologne, Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.
  • Rosenwald A; Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), German Hodgkin Study Group (GHSG), University of Cologne, Cologne, Germany.
  • Sasse S; Department of Pathology, University of Würzburg, Würzburg, Germany.
  • Diepstra A; Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), German Hodgkin Study Group (GHSG), University of Cologne, Cologne, Germany.
  • Borchmann P; Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Engert A; Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), German Hodgkin Study Group (GHSG), University of Cologne, Cologne, Germany.
  • Klapper W; Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), German Hodgkin Study Group (GHSG), University of Cologne, Cologne, Germany.
  • von Bergwelt-Baildon M; Institute of Pathology, University of Kiel, Kiel, Germany.
  • Bröckelmann PJ; Department of Internal Medicine III, University Hospital, Ludwig Maximilians University, Munich, Germany.
  • Schlößer HA; Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), German Hodgkin Study Group (GHSG), University of Cologne, Cologne, Germany. paul.broeckelmann@uk-koeln.de.
Leukemia ; 36(3): 760-771, 2022 03.
Article em En | MEDLINE | ID: mdl-34584203
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Limite: Female / Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Limite: Female / Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article